Guggenheim Keeps Their Buy Rating on Tenet Healthcare (THC)

Guggenheim analyst Jason Cassorla maintained a Buy rating on Tenet Healthcare today and set a price target of $257.00.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Cassorla is an analyst with an average return of -5.7% and a 42.55% success rate. Cassorla covers the Healthcare sector, focusing on stocks such as Cigna, Centene, and Tenet Healthcare.

In addition to Guggenheim, Tenet Healthcare also received a Buy from Morgan Stanley’s Craig Hettenbach in a report issued on February 3. However, on the same day, TipRanks – xAI downgraded Tenet Healthcare (NYSE: THC) to a Hold.

Based on Tenet Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.29 billion and a net profit of $342 million. In comparison, last year the company earned a revenue of $5.12 billion and had a net profit of $472 million

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in December 2025, Nadja West, a Director at THC sold 2,178.00 shares for a total of $430,089.66.